CJC-1295 No DAC Protocol Guide
CJC-1295 without DAC (also known as Mod GRF 1-29 or Modified GRF) is a short-acting growth hormone-releasing hormone (GHRH) analog with a half-life of approximately 30 minutes. It stimulates pulsatile GH release from the pituitary gland, mimicking natural GH secretion patterns. Best administered before bed to synergize with natural nocturnal GH pulses, CJC-1295 No DAC is most effective when combined with a GHRP such as Ipamorelin for amplified GH output. This protocol covers reconstitution from a 2mg vial with 2mL bacteriostatic water, subcutaneous dosing at 100mcg before bed, and stacking recommendations.
Protocol Overview
- Compound
- CJC-1295 No DAC (Mod GRF 1-29)
- Category
- GHRH Analog / GH Secretagogue
- Mechanism
- Stimulates pulsatile GH release from pituitary somatotrophs via GHRH receptor activation; short-acting for natural GH pulse patterns
- Structure
- 29 amino acids, modified GRF(1-29) with four substitutions for enzymatic stability
- Half-Life
- ~30 minutes
- Vial Size
- 2mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- Once daily (before bed)
- Cycle Length
- 8-12 weeks (no cycling required)
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Standard GH Support | 100 mcg | 1x daily (before bed) | Subcutaneous | 8-12 weeks |
| Conservative Start | 50 mcg | 1x daily (before bed) | Subcutaneous | 2 weeks, then increase |
| Saturation Dose | 100 mcg | 2-3x daily (fasted) | Subcutaneous | 8-12 weeks |
Key principle: CJC-1295 No DAC works best when combined with a GHRP (Ipamorelin, GHRP-2, or Hexarelin) administered at the same time. The GHRH + GHRP combination produces synergistic GH release far exceeding either compound alone. Administer on an empty stomach, as elevated blood sugar and insulin blunt GH release.
Reconstitution Instructions
Materials Needed
- CJC-1295 No DAC 2mg lyophilized vial
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 1,000 mcg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 50 mcg | 0.05 mL | 5 units |
| 100 mcg | 0.10 mL | 10 units |
| 200 mcg | 0.20 mL | 20 units |
| 500 mcg | 0.50 mL | 50 units |
Administration Guide
Injection Sites
- Abdomen: Primary site, subcutaneous
- Thigh: Outer thigh, alternate sides
- Upper arm: Back of arm, alternate
Timing & Storage
- Timing: Before bed on empty stomach (2+ hrs post-meal)
- Fasted state: Critical - insulin/glucose blunts GH release
- Vial duration: ~20 days at 100mcg/day
- Storage (reconstituted): Refrigerate 2-8°C, use within 20 days
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site redness (mild, transient)
- Flushing or warmth after injection
- Mild headache (uncommon)
- Water retention at higher doses
CJC-1295 No DAC is generally well-tolerated with a favorable side effect profile. Unlike GHRPs, it does not significantly raise cortisol or prolactin.
Precautions
- Does not cause receptor desensitization (unlike some GHRPs)
- May elevate IGF-1 - monitor in subjects with cancer history
- Not recommended during pregnancy or breastfeeding
- Use caution with diabetes - GH affects insulin sensitivity
- Avoid high-carb meals near injection time
Stacking Recommendations
Compatible Compounds
- Ipamorelin: Gold standard GHRH + GHRP pairing for synergistic GH
- GHRP-2: Stronger GH release with moderate appetite increase
- Hexarelin: Maximum GH pulse (cycle to avoid desensitization)
- BPC-157: Tissue repair during recovery protocols
- AOD-9604: Fat loss synergy without IGF-1 elevation
Popular Stacks
- Classic GH: CJC-1295 No DAC 100mcg + Ipamorelin 100mcg before bed
- Recovery: CJC/Ipa stack + BPC-157 250mcg + TB-500
- Anti-Aging: CJC/Ipa + Epithalon for telomere + GH support
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| GH Axis | IGF-1, GH (fasting) | Baseline, Week 6, Week 12 |
| Metabolic | Fasting glucose, insulin, HbA1c | Baseline, Week 6 |
| Basic Panel | CBC, CMP | Baseline, Week 8 |
| Thyroid | TSH, Free T3, Free T4 | Baseline, Week 8 |
IGF-1 is the primary marker for sustained GH output and confirms protocol effectiveness. Metabolic markers help track insulin sensitivity changes from elevated GH.
Related Tools & Resources
